What is a clinical trial?

A clinical trial is a research study involving human participants designed to evaluate medical interventions — such as drugs, devices, or behavioral strategies. Trials follow a structured protocol and are registered on ClinicalTrials.gov. They progress through phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale comparison), and Phase 4 (post-market surveillance).

How do I find clinical trials I'm eligible for?

You can search ClinicalTrials.gov or use ClinicalMetric to filter by condition, phase, or location. Each trial listing includes eligibility criteria such as age range, sex, diagnosis, and prior treatment history. Contact the study team directly or ask your physician to refer you to a relevant trial.

Are clinical trials safe to participate in?

Clinical trials are conducted under strict ethical and regulatory oversight, including IRB approval and FDA regulation in the US. All participants must give informed consent after reviewing potential risks and benefits. Phase 1 trials carry more uncertainty, while Phase 3 trials involve interventions with an established safety profile. Participation is always voluntary and you may withdraw at any time.

What are the phases of clinical trials?

Clinical trials progress through four main phases. Phase 1 tests safety and dosing in a small group (20–80 people). Phase 2 evaluates efficacy and side effects in a larger group (100–300). Phase 3 compares the intervention against standard treatments in thousands of participants. Phase 4 occurs after approval and monitors long-term effects in the general population.

Do participants get paid for joining clinical trials?

Many clinical trials offer compensation for time and travel expenses, though payment structures vary widely by study. Compensation is not intended to be coercive. Some trials also cover treatment costs for participants. Always review the consent form carefully and ask the study coordinator about any financial considerations before enrolling.

Obesity Clinical Trials 2026: New Weight Loss Drugs Beyond Ozempic

Medical Notice

This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.

Summary

The obesity treatment landscape has been transformed by GLP-1 receptor agonists — semaglutide (Wegovy) achieves ~15% body weight loss, tirzepatide (Zepbound) achieves ~22%. But the next generation of obesity drugs in 2026 trials is targeting even greater weight loss, with triple agonists, amylin analogs, and oral formulations. Several compounds in Phase 3 trials are showing 25–30%+ weight reduction — approaching bariatric surgery outcomes without the procedure.

Triple Receptor Agonists

Retatrutide (Eli Lilly): A GIP/GLP-1/glucagon triple agonist showing 24% mean weight loss at 48 weeks in Phase 2 — the highest weight loss ever seen in a pharmacological trial at that point. Phase 3 TRIUMPH trials are actively recruiting patients with BMI ≥30 or ≥27 with weight-related comorbidity.

Mazdutide (Innovent): GLP-1/glucagon dual agonist in Phase 3 in China, Phase 2 globally, showing ~15% weight loss with metabolic benefits beyond GLP-1 alone.

Amylin-Based Therapies

Cagrilintide + semaglutide (CagriSema): Combining an amylin analog with semaglutide. Phase 3 REDEFINE trials showed ~22–25% weight loss — potentially superior to either drug alone. Novo Nordisk is pursuing FDA approval.

Amycretin: A single molecule combining GLP-1 agonism and amylin receptor activity in one drug. Phase 1/2 results showed 22% weight loss with weekly injection and 13% with oral formulation — remarkable for an oral drug. Phase 3 is beginning in 2026.

Oral Weight Loss Drugs

Orforglipron (Eli Lilly) — an oral non-peptide GLP-1 agonist with no food restriction requirement — is in Phase 3 (ATTAIN trials) for obesity, showing ~9–15% weight loss. Danuglipron (Pfizer) is in Phase 3. These oral options are critical for the large proportion of patients with needle phobia or practical barriers to injection.

Muscle Preservation: The Next Challenge

A key concern with GLP-1-driven weight loss is that 25–40% of lost weight is lean muscle mass. Trials are testing bimagrumab (anti-ActRII antibody) to selectively reduce fat while preserving or increasing muscle. LY3463251 (anti-GDF15) and other agents targeting muscle wasting pathways are in Phase 2 for use alongside GLP-1 drugs.

Who Can Join Obesity Trials

Most obesity trials require: BMI ≥30 kg/m², or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Prior GLP-1 use may be an exclusion criterion in some trials. Stable weight for ≥3 months before screening is typically required, as is willingness to adhere to lifestyle counseling provided as part of the trial.